Vyndaqel

Vyndaqel (tafamidis) is an oral medication used to treat transthyretin amyloidosis. This rare disease affects protein folding, leading to amyloid buildup. Vyndaqel helps stabilize proteins to slow disease progression. It is prescribed for adults with specific genetic mutations.

Vyndaqel is prescribed to treat transthyretin amyloidosis, a condition where abnormal proteins build up in tissues and organs. It is used for adults with hereditary transthyretin-mediated amyloidosis to delay nerve damage and improve quality of life. The medication works by stabilizing the transthyretin protein, preventing it from misfolding and forming amyloid deposits. It is not a cure but may slow disease progression.

Vyndaqel may help reduce symptoms like numbness, weakness, and pain associated with nerve damage. Some patients report improved mobility and daily functioning over time. It is taken as a once-daily capsule, and effects vary by individual. Regular monitoring by a healthcare provider is recommended to assess progress.

Vyndaqel should be taken exactly as prescribed by a healthcare professional. Inform your doctor about all medications and supplements you are using. Pregnant or breastfeeding women should discuss risks with their doctor before starting treatment. Liver function tests may be required periodically to monitor for side effects.

Vyndaqel may interact with medications that affect liver enzymes, such as certain antibiotics or antifungals. Avoid alcohol while taking this medication, as it may increase the risk of side effects. Always inform your healthcare provider about all prescription, over-the-counter, and herbal products you are using to prevent potential interactions.